Historically, there have been some distinct differences between the markets for surgical sealants, glues and wound closure in the United States and Japan. Â In part, this arises from Japan’s earlier adoption of emerging wound closure technologies than the U.S., particularly surgical sealants, which had delayed U.S. introduction due to concerns about blood-borne virus transmission. Â While those differences have largely been dissipated by several years of active fibrin sealant marketing in the U.S., there remain other difference due to differences in clinical practice, product adoption, economics and other forces.
Below is illustrated the relative distribution of the surgical sealants, glues and wound closure markets (excluding sutures/staples) in the U.S. and Japan.
Source: MedMarket Diligence, LLC; (pending) report #s180, “Surgical Sealants, Glues, Wound Closure and Anti-Adhesion 2010-2015.”
There are a number of potential reasons (we are exploring) behind the differences, including the relatively higher hemostat usage in the USA and the relatively higher hi-strength adhesive and post-surgical adhesion product usage in Japan. Â In part, both of these differences reflect an advanced market in Japan where, arguably, two of the most emerging areas of the “securement” market include high strength glues and post-surgical adhesion products, the two areas where the relative difference is greatest. Â In terms of hemostats, these represent a broad range of product types (collagens, gels, others) that have been more well established in the U.S., but which show less product and technical development than high strength glues and post-surgical adhesion products.